Paclibenz-260 mg Injection 43.4 ml

Paclibenz-260 mg Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer. 
 
Paclibenz-260 mg Injection 43.4 ml contains ‘Paclitaxel’, which works by stopping cell division and preventing the growth of certain cancer cells. 
 
In some cases, Paclibenz-260 mg Injection 43.4 ml may cause common side effects, such as nausea, vomiting, mild diarrhoea, and joint or muscle pain. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.
 
Consult your doctor if you are pregnant, breastfeeding, think you may be pregnant or are planning pregnancy. Paclibenz-260 mg Injection 43.4 ml is not recommended for children below 18 years. Inform your doctor about your health condition and medications to rule out any side effects.

Paclibenz-260 mg Injection 43.4 ml belongs to the group of anti-cancer medicines called anti-microtubule agents used to treat various types of cancers, including ovarian and breast cancer (in advanced/spreading state or after surgery) and advanced-stage non-small cell lung cancer. It may also be used when other treatments have failed or in combination with other treatments. Paclibenz-260 mg Injection 43.4 ml may also be indicated in patients with Kaposi’s sarcoma (cancer that develops from the cells that line lymph or blood vessels) associated with AIDS (Acquired Immuno-Deficiency Syndrome), where other treatments have not been effective. Paclibenz-260 mg Injection 43.4 ml contains ‘Paclitaxel’, which works by preventing the growth of certain cancer cells. 

• Nausea
• Vomiting
• Diarrhoea
• Hair loss
• Joint or muscle pain
• Decreased blood cell count

Do not take Paclibenz-260 mg Injection 43.4 ml if you are allergic to any of its components, if your white blood cell or platelet count is very low, if you have a serious uncontrolled infection, and Paclibenz-260 mg Injection 43.4 ml has to be given for the treatment of Kaposi’s sarcoma (cancer that causes lesions in soft tissues), or if you have severe liver problems. Inform your doctor if you have heart disease, abnormal blood cell counts, irregular heartbeat, tingling, numbness, or burning sensation in fingers or toes, visual problems, if you are on radiation therapy, or if you have Kaposi’s sarcoma and have a sore or inflamed mouth. Also, inform your doctor if you are pregnant, breastfeeding, think you are pregnant or planning pregnancy.

• RIFAMPICIN
• ERYTHROMYCIN
• KETOCONAZOLE
• FLUOXETINE
• CARBAMAZEPINE
• PHENYTOIN
• GEMFIBROZIL
• CIMETIDINE
• RITONAVIR
• SAQUINAVIR
• INDINAVIR
• NELFINAVIR
• EFAVIRENZ
• NEVIRAPINE
• CLOPIDOGREL

• Your doctor may advise regular blood tests to check for liver activity, kidney function and blood cell count.
• You and/or your partner should use reliable contraception during treatment with Paclibenz-260 mg Injection 43.4 ml and for at least six months after the treatment.

• Eat a healthy diet and exercise regularly to maintain proper weight.
• Avoid smoking and alcohol consumption.
• Include leafy vegetables, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, herbs and spices in your diet.
• Avoid fast food, fried food, processed meats, refined carbs and added sugar.
• Get optimal sleep; rest well.